Print

Print


Two copies of G2019S Parkinson's gene mutation doesn't lead to more severe
disease
No observable differences between homozygous and heterzygous state
A group of Parkinson's disease researchers concluded there are no observable
differences between those who have two copies of the most common mutation of
the recently discovered LRRK2 gene and those who have only one copy. Their
study will be published in the September edition of the Archives of
Neurology.
In most diseases with a genetic cause or component, two copies of a bad gene
lead to more severe visible manifestation of the disease. Researchers
expected to see worse symptoms, the disease start earlier in life and a
shorter life span for those with two copies of the LRRK2 gene with the G2019S
mutation. "That proved not to be the case," says Mayo Clinic neurologist
Zbigniew Wszolek, M.D.
Wszolek formed an international consortium that compared the clinical features
of Parkinson's disease in the two groups. "It's puzzling," he says. "More
studies are needed. More patients need to be identified and, hopefully, more
basic science research is going to be performed to find out why."
The G2019S mutation is the most common of the 20 identified LRRK2
disease-causing mutations. There are six known genes that cause familial
Parkinson's disease, but only one, the G2019S mutation of the LRRK2 gene, has
been associated with previously unexplained cases of Parkinson's disease.
Wszolek and his colleagues hope that studying the ways in which these genes
cause disease, especially the G2019S mutation, will lead to improved
treatments and even a cure. "We are all united by the common drive to learn
more about this disease, to help the people with this illness and to bring us
closer to curative treatments," Wszolek says. "And this may be a step in that
direction."
By pooling their studies from around the globe, Wszolek and his colleagues
found 26 people with the G2019S mutation in both copies of their LRRK2
gene--one inherited from the mother and the other from the father.
Interestingly, three patients with the dual mutation exhibited no clinical
signs of Parkinson's disease, an indication that the gene has incomplete
penetrance.
This concept means having the gene mutation alone does not lead to developing
severe symptoms or even developing any signs of the disease 100 percent of
the time. "One may need some additional factors, either genetic or
environmental, which work either to produce the disease or to protect one
from developing it," Wszolek says.
This latest finding supports the theory many hold that the majority of
Parkinson's disease cases may only be explained by the interaction of a
number of genes or a genetic and environmental interaction.
Wszolek and his colleagues found all patients in their study, whether they had
one or two G2019S mutations, had asymmetric onset of symptoms, most often
tremor, no male or female preponderance, and both groups had a similar range
in the age in which symptoms began.
In 2004 Wszolek was one of the researchers who discovered the LRRK2 gene
caused parkinsonism. He was also part of the team that discovered the G2019S
mutation causes parkinsonism in several North American and European families.
That was the first time a genetic cause had been associated with typical,
late-onset Parkinson's disease.
###

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn